COVID-19 Medical Countermeasure Experiences and Lessons Learned: Virtual Workshop, Aug 3

Timely, safe, and effective utilization of medical countermeasures (MCM) are critical components during a public health emergency involving a high-consequence threat or an emerging infectious disease, such as the COVID-19 pandemic.  

NACCHO in partnership with the CDC will conduct workshops to collect feedback from public health stakeholders and their partners on distribution and use of medical countermeasures (MCM) during the COVID-19 pandemic response. The listening session will focus on monoclonal antibodies and oral therapeutics used for COVID-19. This session will be held on Wednesday, August 3, 1:00-4:00 pm ET.  
Public health stakeholders involved in the distribution, administration, monitoring, or reporting of monoclonal antibodies and oral therapeutics are invited to express their interest in participating in this listening session. We ask that those interested in participating bring representatives from partners (such as health care, pharmacy, and other clinical partners) involved in the distribution, administration, monitoring, or reporting. 
Information from the workshops will be used to inform opportunities for new and additional integration and collaboration across the MCM response spectrum. Results will also be used to enhance MCM response across different threats (e.g., anthrax, botulism, smallpox, Ebola) and MCM categories (e.g., drugs, biologics, vaccines).  

NACCHO will select local jurisdiction teams to participate in the workshop. Not all who complete the below form will be selected for the listening sessions due to capacity limits in the workshops. 

Workshop Date: August 3, 1:00-4:00 pm ET 


Please respond by July 22.

For questions, please contact Jessica Pryor at  

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s